Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment.
Perrin
Christophe
C
Fabre
Cédric
C
Raoul
Jean-Luc
JL
Boucher
Eveline
E
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy; D006801:Humans; D008275:Magnesium Deficiency / Q000139:chemically induced* / Q000150:complications; D008297:Male; D001523:Mental Disorders / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab